Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial
Introduction The aim of this study is to evaluate the efficacy of duloxetine augmentation in treatment of resistant obsessive-compulsive disorder ( OCD ) . Methods This augmentation trial was design ed as an 8-week r and omized controlled , double-blind study . Forty-six patients experiencing OCD who had failed to respond to at least 12 weeks of treatment with a selective serotonin reuptake inhibitor ( fluoxetine , citalopram , or fluvoxamine ) were r and omly allocated to receive duloxetine or sertraline plus their current anti-OCD treatment . The Yale-Brown Obsessive Compulsive Scale ( Y-BOCS ) was the primary outcome measure . Treatment response was defined as 25 % or more decrease in scores of Y-BOCS . The mean dosage of duloxetine was 44.4 mg/d ( range , 20–60 mg/d ) , and the mean dosage of sertraline was 123.8 mg/d ( range , 50–200 mg/d ) . Results Forty-six patients ( 24 of 30 in duloxetine group and 22 of 27 in sertraline group ) completed the trial . Both groups showed improvement during the 8-week study period ( mean Y-BOCS total score at week 8 as compared with baseline : P < 0.001 & P < 0.001 ) without significant difference ( P = 0.861 ) . Those receiving duloxetine plus their initial medications experienced a mean decrease of 33.0 % in Y-BOCS score , and the patients with sertraline added to their initial medication experienced a mean decrease of 34.5 % in Y-BOCS . Discussion Our double-blind controlled clinical trial showed duloxetine to be as effective as sertraline in reducing obsessive and compulsive symptoms in patients with resistant OCD . However , it needs to be noted that our study is preliminary , and larger double-blind placebo-controlled studies are necessary to confirm the results
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .